Huali Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huali Fan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Fu Peng
West China School of Pharmacy, Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University
2 shared publications - Cheng Peng
State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
1 shared publication Ruixin Wang
West China School of Pharmacy, Department of Pharmacy, West China Tianfu Hospital, West China Hospital, Sichuan University
1 shared publication- Sui Li
Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
1 shared publication Xiaofang Xie
Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine
1 shared publication- Xiaoqi Pan
School of Pharmacy and School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu City, Sichuan Province, 611137, China; R&D Center for Efficiency, Safety and Application in Chinese Materia Medica with Medical and Edible Values, Chengdu University of Traditional Chinese Medicine, Chengdu City, Sichuan Province, 611137, China
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1859886
Lysosome-dependent cell death in hepatocellular carcinoma: unlocking the therapeutic potential of natural products
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and the available targeted therapies (e.g., sorafenib, lenvatinib) have limited options and frequent drug resistance. Lysosome-dependent cell death (LDCD), characterized by increased lysosomal membrane permeabilization (LMP) and the release of proteases, has attracted considerable attention as a non-apoptotic mechanism that can circumvent drug resistance. In recent years, researchers have used natural compounds in the treatment of HCC, which effectively induce LDCD through a variety of mechanisms, such as acid sphingomyelinase inhibition, lysosomal-iron-ferroptosis axis activation, lysosomal pH regulation, PI3K/AKT/mTOR-TFEB pathway inhibition and so on. These compounds synergize with conventional targeted agents to overcome drug resistance through direct cytotoxicity or targeting hypertrophic lysosomal drug release. This article reviews the regulation of LDCD and the role of natural products in HCC based on PubMed, Web of Science and CNKI databases, aiming to providing a reference for the treatment of drug-resistant liver cancer.
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1859886
Open AccessLysosome-dependent cell death in hepatocellular carcinoma: unlocking the therapeutic potential of natural products
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and the available targeted therapies (e.g., sorafenib, lenvatinib) have limited options and frequent drug resistance. Lysosome-dependent cell death (LDCD), characterized by increased lysosomal membrane permeabilization (LMP) and the release of proteases, has attracted considerable attention as a non-apoptotic mechanism that can circumvent drug resistance. In recent years, researchers have used natural compounds in the treatment of HCC, which effectively induce LDCD through a variety of mechanisms, such as acid sphingomyelinase inhibition, lysosomal-iron-ferroptosis axis activation, lysosomal pH regulation, PI3K/AKT/mTOR-TFEB pathway inhibition and so on. These compounds synergize with conventional targeted agents to overcome drug resistance through direct cytotoxicity or targeting hypertrophic lysosomal drug release. This article reviews the regulation of LDCD and the role of natural products in HCC based on PubMed, Web of Science and CNKI databases, aiming to providing a reference for the treatment of drug-resistant liver cancer.
- Open Access
- 14 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14) , 7526
MicroRNAs in Epithelial–Mesenchymal Transition Process of Cancer: Potential Targets for Chemotherapy
In the last decades, a kind of small non-coding RNA molecules, called as microRNAs, has been applied as negative regulators in various types of cancer treatment through down-regulation of their targets. More recent studies exert that microRNAs play a critical role in the EMT process of cancer, promoting or inhibiting EMT progression. Interestingly, accumulating evidence suggests that pure compounds from natural plants could modulate deregulated microRNAs to inhibit EMT, resulting in the inhibition of cancer development. This small essay is on the purpose of demonstrating the significance and function of microRNAs in the EMT process as oncogenes and tumor suppressor genes according to studies mainly conducted in the last four years, providing evidence of efficient target therapy. The review also summarizes the drug candidates with the ability to restrain EMT in cancer through microRNA regulation.
- 14 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14) , 7526
Open AccessMicroRNAs in Epithelial–Mesenchymal Transition Process of Cancer: Potential Targets for Chemotherapy
In the last decades, a kind of small non-coding RNA molecules, called as microRNAs, has been applied as negative regulators in various types of cancer treatment through down-regulation of their targets. More recent studies exert that microRNAs play a critical role in the EMT process of cancer, promoting or inhibiting EMT progression. Interestingly, accumulating evidence suggests that pure compounds from natural plants could modulate deregulated microRNAs to inhibit EMT, resulting in the inhibition of cancer development. This small essay is on the purpose of demonstrating the significance and function of microRNAs in the EMT process as oncogenes and tumor suppressor genes according to studies mainly conducted in the last four years, providing evidence of efficient target therapy. The review also summarizes the drug candidates with the ability to restrain EMT in cancer through microRNA regulation.